# US 2025/0145632 A1 · Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145632 A1
- Document ID: US20250145632A1
- Status: Published application
- Kind: A1
- Application number: 18/721,125
- Filed: 2022-12-21
- Published: 2025-05-08
- Earliest claimed: 2021-12-22
- Assignees: Insilico Medicine IP Limited
- Applicants: Insilico Medicine IP Limited
- Inventors: Hongfu LU; Jingjing PENG; Xiao DING; Jinxin LIU; Yingtao LIU; Feng REN; Fusheng ZHOU; Tao JIANG; Tao LIANG; Jiong LAN; Qiang LU
- Web page: https://patentgrep.com/patent/US20250145632A1

## CPC

- C07D 487/22: in which the condensed system contains four or more hetero rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- C07D 471/22: in which the condensed systems contains four or more hetero rings
- C07D 487/16: Peri-condensed systems
- C07D 487/18: Bridged systems
- C07D 498/16: Peri-condensed systems
- C07D 498/18: Bridged systems
- C07D 498/22: in which the condensed system contains four or more hetero rings
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention discloses a pyrimidine heterocyclic compound, and a preparation method and medical use thereof. Specifically, the present invention discloses a pyrimidine heterocyclic compound with a structure shown in Formula (A) or a pharmaceutically acceptable salt thereof (groups are each defined in the specification), a pharmaceutical composition comprising the compound, and use of the compound in treatment of cell proliferative diseases (such as cancers).

## Claims

### Claim 1

A compound shown in Formula (A) or a pharmaceutically acceptable salt thereof,
ring A is none; or the ring A is selected from the group consisting of 3-14 membered carbocycle, 3-14 membered heterocycle, 5-12 membered heteroaryl and C5-12 aryl; the ring A is unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from a group S1; the 3-14 membered heterocycle has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
L3 is none, C1-6 alkylene, C2-6 alkenylene or ring B, wherein 1, 2, 3, 4 or 5 hydrogen atoms on the C1-6 alkylene may be each independently and optionally substituted by R13; 1, 2, 3, 4 or 5 hydrogen atoms on the C2-6 alkenylene may be each independently and optionally substituted by R13;
the ring B is selected from the group consisting of 3-14 membered carbocycle, 3-14 membered heterocycle, 5-12 membered heteroaryl and C5-12 aryl; the ring B is unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1; the 3-14 membered heterocycle has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
L1 is none, C1-6 alkylene, C2-6 alkenylene, —O—, —NR10—, —C═N—, C5-12 aryl, 5-12 membered heteroaryl, —C(O)—, —C(O)—NR10— or —NR10—C(O)—, wherein 1, 2, 3, 4 or 5 hydrogen atoms on the C1-6 alkylene may be each independently and optionally substituted by R13; 1, 2, 3, 4 or 5 hydrogen atoms on the C2-6 alkenylene may be each independently and optionally substituted by R13; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the C5-12 aryl and the 5-12 membered heteroaryl are each independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1;
L2 is selected from the group consisting of:
—(O)m2—(CR13R14)m1—(NR12)m3—,
—(NR11)m2—(CR13R14)m1—(NR12)m3—,
—(O)m2—(CR13R14)m5-(3-7 membered carbocyclyl)m4-(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5-(3-7 membered carbocyclyl)m4-(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5-(3-7 membered heterocyclyl)m4-(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5-(3-7 membered heterocyclyl)m4-(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—NR10—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—NR10—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—NR10C(O)—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—NR10C(O)—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—C(O)NR10—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—C(O)NR10—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—O—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—O—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—OC(O)—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—OC(O)—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—C(O)O—(CR13R14)m6—(NR12)m3,
—(NR11)m2—(CR13R14)m5—C(O)O—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—(CH═CH)m7—(CR13R14)m6—(NR12)m3—, and
—(NR11)m2—(CR13R14)m5—(CH═CH)m7—(CR13R14)m6—(NR12)m3—;
each R10 is independently hydrogen, C1-6 alkyl, deuterated C1-6 alkyl, -3-7 membered carbocyclyl, —C(O)—C1-6 alkyl, —C(O)—C1-4 alkyl-C1-6 alkoxy, —C(O)-3-7 membered carbocyclyl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-NHC(O)—C1-6 alkyl, —C1-4 alkyl-NHC(O)—C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-NHC(O)-3-7 membered carbocyclyl, or —C1-4 alkyl-NRR′;
each 3-7 membered heterocyclyl independently has 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 3-7 membered carbocycle is each independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1;
each 3-7 membered carbocyclyl is independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1;
each R11 is independently hydrogen, C1-6 alkyl or deuterated C1-6 alkyl;
each R12 is independently hydrogen, C1-6 alkyl or deuterated C1-6 alkyl;
each R13 is independently hydrogen, cyano, hydroxyl, halogen, C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, -3-7 membered carbocyclyl, —C0-6 alkylene-NRR′, —C1-6 alkylene-hydroxyl or —C0-6 alkylene-cyano;
each R14 is independently hydrogen, cyano, hydroxyl, halogen, C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, -3-7 membered carbocyclyl, —C0-6 alkylene-NRR′, —C1-6 alkylene-hydroxyl or —C0-6 alkylene-cyano;
each m1 is independently 1, 2, 3, 4, 5 or 6;
each m2 is independently 0 or 1;
each m3 is independently 0 or 1;
each m4 is independently 1 or 2;
each m5 is independently 0, 1, 2, 3, 4, 5 or 6;
each m6 is independently 0, 1, 2, 3, 4, 5 or 6;
each m7 is independently 1 or 2;
R1 is hydrogen, halogen, cyano, C1-6 alkyl or 3-14 membered carbocyclyl; the C1-6 alkyl and the 3-14 membered carbocyclyl are independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group consisting of oxo, hydroxyl, halogen, C1-6 alkyl and halogenated C1-6 alkyl;
R2 is hydrogen, halogen, cyano, C1-6 alkyl or 3-14 membered carbocyclyl; the C1-6 alkyl and the 3-14 membered carbocyclyl are independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group consisting of oxo, hydroxyl, halogen, C1-6 alkyl and halogenated C1-6 alkyl;
X2 is N or C(R3);
X1 is N or C(R4);
Y is N or C(R4);
Z is N or C(R3);
each R3 is independently hydrogen, halogen, cyano, C1-6 alkyl or halogenated C1-6 alkyl;
each R4 is independently hydrogen, halogen, hydroxyl, cyano, —C2-4 alkenylene-phenyl, —C2-4 alkynylene-phenyl, —S(O)—OH, —S(O)2—OH, —S—(C1-6 alkyl), C1-6 alkyl, —O—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —O—C1-6 alkylene-O—C1-6 alkyl, —C0-6 alkylene-NRR′, —C0-6 alkylene-C(O)OH, —C0-6 alkylene-C(O)—C1-6 alkyl, —C0-6 alkylene-C(O)—NRR′, —C0-6 alkylene-NR—C(O)—C1-6 alkyl, —C0-6 alkylene-S(O)2—C1-6 alkyl, —C0-6 alkylene-S(O)2—NRR′, —C0-6 alkylene-NR—S(O)2—C1-6 alkyl, —C0-6 alkylene-NR—S(O)2—NRR′, —C0-6 alkylene-P(O)O—(C1-6 alkyl)2, —C0-6 alkylene-P(O)—(C1-6 alkyl)(O—C1-6 alkyl), —C0-6 alkylene-P(O)—(C1-6 alkyl)2, —C0-6 alkylene-3-14 membered carbocyclyl, —C0-6 alkylene-3-14 membered heterocyclyl, —C0-6 alkylene-5-12 membered heteroaryl, —C0-6 alkylene-C5-12 aryl, —C0-6 alkylene-C(O)-3-14 membered heterocyclyl, —C0-6 alkylene-C(O)-5-12 membered heteroaryl, —O—C0-6 alkylene-O—C1-6 alkyl, —O—C0-6 alkylene-3-14 membered carbocyclyl, —O—C0-6 alkylene-3-14 membered heterocyclyl, —O—C0-6 alkylene-5-12 membered heteroaryl, —O—C0-6 alkylene-C5-12 aryl, and —S(O)—C1-6 alkyl, wherein the C1-6 alkyl, the C0-6 alkylene, the C2-4 alkenylene, the 3-14 membered carbocyclyl, the 3-14 membered heterocyclyl, the 5-12 membered heteroaryl and the C5-12 aryl are independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1; the 3-14 membered heterocycle has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
the groups in the group S1 comprise: oxo (═O), halogen, hydroxyl, cyano, C1-6 alkyl, —O—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —O—C1-6 alkylene-O—C1-6 alkyl, —C0-6 alkylene-NRR′, —C0-6 alkylene-C(O)OH, —C0-6 alkylene-C(O)—C1-6 alkyl, —C0-6 alkylene-C(O)—NRR′, —C0-6 alkylene-NR—C(O)—C1-6 alkyl, —C0-6 alkylene-S(O)2—C1-6 alkyl, —C0-6 alkylene-S(O)2—NRR′, —C0-6 alkylene-NR—S(O)2—C1-6 alkyl, —C0-6 alkylene-NR—S(O)2—NRR′, —C0-6 alkylene-P(O)O—(C1-6 alkyl)2, —C0-6 alkylene-P(O)—(C1-6 alkyl)(O—C1-6 alkyl), —C0-6 alkylene-P(O)—(C1-6 alkyl)2, —C0-6 alkylene-3-14 membered carbocyclyl, —C0-6 alkylene-3-14 membered heterocyclyl, —C0-6 alkylene-5-12 membered heteroaryl, —C0-6 alkylene-C5-12 aryl, —C0-6 alkylene-C(O)-3-14 membered heterocyclyl, —C0-6 alkylene-C(O)-5-12 membered heteroaryl, —O—C0-6 alkylene-O—C1-6 alkyl, —O—C0-6 alkylene-3-14 membered carbocyclyl, —O—C0-6 alkylene-3-14 membered heterocyclyl, —O—C0-6 alkylene-5-12 membered heteroaryl, —O—C0-6 alkylene-C5-12 aryl, and —S(O)—C1-6 alkyl;
R and R′ are each independently hydrogen, C1-6 alkyl or deuterated C1-6 alkyl, or R and R′ optionally form the 3-14 membered heterocyclyl or 5-12 membered heteroaryl together with nitrogen atoms connected to R and R′, wherein the heterocyclyl and the heteroaryl each independently contain 0, 1 or 2 heteroatoms selected from N, O and S in addition to the existing nitrogen atoms;
in the above groups, 2 hydrogen atoms on any one carbon atom on the C0-6 alkylene may further be optionally substituted by 3-7 membered carbocycle or 3-7 membered heterocyclic spirocycle at the same time; and
in the above groups, 2 hydrogen atoms on any one carbon atom on the C1-6 alkylene may further be optionally substituted by 3-7 membered carbocycle or 3-7 membered heterocyclic spirocycle at the same time.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound shown in Formula (A) is a compound shown in Formula (I-A):
wherein X1, Y, Z, X2, R1, R2, L1, L2, ring A and ring B are each defined as in claim 1;
or
the compound shown in Formula (A) is a compound shown in Formula (I-B):
wherein X1, Y, Z, X2, R1, R2, L1, L2, ring A, R13 and R14 are each defined as in claim 1, and m0 is 1, 2, 3, 4, 5 or 6;
or
the compound shown in Formula (A) is a compound shown in Formula (A1):
wherein X1, Y, Z, X2, R1, R2, L1, L2, ring A and ring B are each defined as in claim 1;
or
the compound shown in Formula (A) is a compound shown in Formula (A2):
wherein X1, Y, Z, X2, R1, R2, L1, L2, ring A, R and R14 are each defined as in claim 1, and m c is 1, 2, 3, 4, 5 or 6.

### Claim 3 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound shown in Formula (A) is a compound shown in Formula (II-A):
wherein R1, R2, L1, L2, ring A, ring B and X1 are each defined as in claim 1;
or
the compound shown in Formula (A) is a compound shown in Formula (II-B):
wherein X1, R1, R2, L1, L2, ring A, R and R4 are each defined as in claim 1, and m is 1, 2, 3, 4, 5 or 6;
or
the compound shown in Formula (A) is a compound shown in Formula (A3):
wherein X1, R1, R2, L1, L2, ring A and ring B are each defined as in claim 1;
or
the compound shown in Formula (A) is a compound shown in Formula (A4):
wherein X1, R1, R2, L1, L2, ring A, R13 and R14 are each defined as in claim 1, and m0 is 1, 2, 3, 4, 5 or 6.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
the compound shown in Formula (A) is a compound shown in Formula (III-A):
wherein L1, L2, ring A, ring B and X1 are each defined as in claim 1;
or
the compound shown in Formula (A) is a compound shown in Formula (III-B):
wherein X1, L1, L2, ring A, R13 and R14 are each defined as in claim 1, and m0 is 1, 2, 3, 4, 5 or 6;
or
the compound shown in Formula (A) is a compound shown in Formula (A5):
wherein X1, L1, L2, ring A and ring B are each defined as in claim 1;
or
the compound shown in Formula (A) is a compound shown in Formula (A6):
wherein X1, L1, L2, ring A, R13 and R14 are each defined as in claim 1, and m0 is 1, 2, 3, 4, 5 or 6;
or, the compound shown in Formula (A) is a compound shown in Formula (IV-a):
wherein X1, L1, L2 and ring B are each defined as in claim 1;
or, the compound shown in Formula (A) is a compound shown in Formula (IV-b):
wherein X1, L1, L2 and ring B are each defined as in claim 1;
wherein X1, L1, L2 and ring B are each defined as in claim 1.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the ring A is none; or the ring A is selected from the group consisting of a cyclobutyl ring, a cyclopentyl ring, a cyclohexyl ring, a piperidinyl ring, a piperazinyl ring, a tetrahydropyrrolidinyl ring, a pyrazolyl ring, an imidazolyl ring and a pyridinyl ring; the ring A is unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1.

### Claim 6 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the ring B is selected from the group consisting of a cyclobutyl ring, a cyclopentyl ring, a cyclohexyl ring, a piperidinyl ring, a piperazinyl ring, a tetrahydropyrrolidinyl ring, a pyrazolyl ring and an imidazolyl ring; the ring B is unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1.

### Claim 7 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein X1 is N or C(R4), and R4 is hydrogen, halogen, cyano, —S(O)2CH3 or —P(O)(CH3)2.

### Claim 8 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from Table (I).

### Claim 9 (depends on 1)

A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 10

A method for preventing and/or treating a CDK7-related disease in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of a compound shown in Formula (A) or a pharmaceutically acceptable salt thereof,
ring A is none; or the ring A is selected from the group consisting of 3-14 membered carbocycle, 3-14 membered heterocycle, 5-12 membered heteroaryl and C5-12 aryl; the ring A is unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from a group S1; the 3-14 membered heterocycle has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
L3 is none, C1-6 alkylene, C2-6 alkenylene or ring B, wherein 1, 2, 3, 4 or 5 hydrogen atoms on the C1-6 alkylene may be each independently and optionally substituted by R13; 1, 2, 3, 4 or 5 hydrogen atoms on the C2-6 alkenylene may be each independently and optionally substituted by R13;
the ring B is selected from the group consisting of 3-14 membered carbocycle, 3-14 membered heterocycle, 5-12 membered heteroaryl and C5-12 aryl; the ring B is unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1: the 3-14 membered heterocycle has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
L1 is none, C1-6 alkylene, C2-6 alkenylene, —O—, —NR10—, —C═N—, C5-12 aryl, 5-12 membered heteroaryl, —C(O)—, —C(O)—NR10— or —NR10—C(O)—, wherein 1, 2, 3, 4 or 5 hydrogen atoms on the C1-6 alkylene may be each independently and optionally substituted by R13: 1, 2, 3, 4 or 5 hydrogen atoms on the C2-6 alkenylene may be each independently and optionally substituted by R13; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the C5-12 aryl and the 5-12 membered heteroaryl are each independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1;
L2 is selected from the group consisting of:
—(O)m2—(CR13R14)m1—(NR12)m3—,
—(NR11)m2—(CR13R14)m1—(NR12)m3—,
—(NR11)m2—(CR13R14)m5-(3-7 membered carbocyclyl)m4-(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5-(3-7 membered heterocyclyl)m4-(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5-(3-7 membered heterocyclyl)m4-(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—NR10—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—NR10—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—NR10C(O)—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—NR10C(O)—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—C(O)NR10—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—C(O)NR10—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—O—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—O—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—OC(O)—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—OC(O)—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—C(O)O—(CR13R14)m6—(NR12)m3—,
—(NR11)m2—(CR13R14)m5—C(O)O—(CR13R14)m6—(NR12)m3—,
—(O)m2—(CR13R14)m5—(CH═CH)m7—(CR13R14)m6—(NR12)m3—, and
—(NR11)m2—(CR13R14)m5—(CH═CH)m7—(CR13R14)m6—(NR12)m3—;
each R10 is independently hydrogen, C1-6 alkyl, deuterated C1-6 alkyl, -3-7 membered carbocyclyl, —C(O)—C1-6 alkyl, —C(O)—C1-4 alkyl-C1-6 alkoxy, —C(O)-3-7 membered carbocyclyl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-NHC(O)—C1-6 alkyl, —C1-4 alkyl-NHC(O)—C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-NHC(O)-3-7 membered carbocyclyl, or —C1-4 alkyl-NRR′;
each 3-7 membered heterocyclyl independently has 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 3-7 membered carbocycle is each independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1;
each 3-7 membered carbocyclyl is independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1;
each R11 is independently hydrogen, C1-6 alkyl or deuterated C1-6 alkyl;
each R12 is independently hydrogen, C1-6 alkyl or deuterated C1-6 alkyl;
each R13 is independently hydrogen, cyano, hydroxyl, halogen, C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, -3-7 membered carbocyclyl, —C0-6 alkylene-NRR′, —C1-6 alkylene-hydroxyl or —C0-6 alkylene-cyano;
each R14 is independently hydrogen, cyano, hydroxyl, halogen, C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, -3-7 membered carbocyclyl, —C0-6 alkylene-NRR′, —C1-6 alkylene-hydroxyl or —C0-6 alkylene-cyano;
each m1 is independently 1, 2, 3, 4, 5 or 6;
each m2 is independently 0 or 1;
each m3 is independently 0 or 1;
each m4 is independently 1 or 2;
each m5 is independently 0, 1, 2, 3, 4, 5 or 6;
each m6 is independently 0, 1, 2, 3, 4, 5 or 6;
each m7 is independently 1 or 2;
R1 is hydrogen, halogen, cyano, C1-6 alkyl or 3-14 membered carbocyclyl; the C1-6 alkyl and the 3-14 membered carbocyclyl are independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group consisting of oxo, hydroxyl, halogen, C1-6 alkyl and halogenated C1-6 alkyl;
R2 is hydrogen, halogen, cyano, C1-6 alkyl or 3-14 membered carbocyclyl; the C1-6 alkyl and the 3-14 membered carbocyclyl are independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group consisting of oxo, hydroxyl, halogen, C1-6 alkyl and halogenated C1-6 alkyl;
X2 is N or C(R3);
X1 is N or C(R4);
Y is N or C(R4);
Z is Nor C(R3);
each R3 is independently hydrogen, halogen, cyano, C1-6 alkyl or halogenated C1-6 alkyl;
each R4 is independently hydrogen, halogen, hydroxyl, cyano, —C2-4 alkenylene-phenyl, —C2-4 alkynylene-phenyl, —S(O)—OH, —S(O)2—OH, —S—(C1-6 alkyl), C1-6 alkyl, —O—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —O—C1-6 alkylene-O—C1-6 alkyl, —C0-6 alkylene-NRR′, —C0-6 alkylene-C(O)OH, —C0-6 alkylene-C(O)—C1-6 alkyl, —C0-6 alkylene-C(O)—NRR′, —C0-6 alkylene-NR—C(O)—C1-6 alkyl, —C0-6 alkylene-S(O)2—C1-6 alkyl, —C0-6 alkylene-S(O)2—NRR′, —C0-6 alkylene-NR—S(O)2—C1-6 alkyl, —C0-6 alkylene-NR—S(O)2—NRR′, —C0-6 alkylene-P(O)O—(C1-6 alkyl)2, —C0-6 alkylene-P(O)—(C1-6 alkyl)(O—C1-6 alkyl), —C0-6 alkylene-P(O)—(C1-6 alkyl)2, —C0-6 alkylene-3-14 membered carbocyclyl, —C0-6 alkylene-3-14 membered heterocyclyl, —C0-6 alkylene-5-12 membered heteroaryl, —C0-6 alkylene-C5-12 aryl, —C0-6 alkylene-C(O)-3-14 membered heterocyclyl, —C0-6 alkylene-C(O)-5-12 membered heteroaryl, —O—C0-6 alkylene-O—C1-6 alkyl, —O—C0-6 alkylene-3-14 membered carbocyclyl, —O—C0-6 alkylene-3-14 membered heterocyclyl, —O—C0-6 alkylene-5-12 membered heteroaryl, —O—C0-6 alkylene-C5-12 aryl, and —S(O)—C1-6 alkyl, wherein the C1-6 alkyl, the C0-6 alkylene, the C2-4 alkenylene, the 3-14 membered carbocyclyl, the 3-14 membered heterocyclyl, the 5-12 membered heteroaryl and the C5-12 aryl are independently unsubstituted or substituted by 1, 2, 3, 4 or 5 groups selected from the group S1; the 3-14 membered heterocycle has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 5-12 membered heteroaryl has 1, 2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
the groups in the group S1 comprise: oxo (═O), halogen, hydroxyl, cyano, C1-6 alkyl, —O—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —O—C1-6 alkylene-O—C1-6 alkyl, —C0-6 alkylene-NRR′, —C0-6 alkylene-C(O)OH, —C0-6 alkylene-C(O)—C1-6 alkyl, —C0-6 alkylene-C(O)—NRR′, —C0-6 alkylene-NR—C(O)—C1-6 alkyl, —C0-6 alkylene-S(O)2—C1-6 alkyl, —C0-6 alkylene-S(O)2—NRR′, —C0-6 alkylene-NR—S(O)2—C1-6 alkyl, —C0-6 alkylene-NR—S(O)2—NRR′, —C0-6 alkylene-P(O)O—(C1-6 alkyl)2, —C0-6 alkylene-P(O)—(C1-6 alkyl)(O—C1-6 alkyl), —C0-6 alkylene-P(O)—(C1-6 alkyl)2, —C0-6 alkylene-3-14 membered carbocyclyl, —C0-6 alkylene-3-14 membered heterocyclyl, —C0-6 alkylene-5-12 membered heteroaryl, —C0-6 alkylene-C5-12 aryl, —C0-6 alkylene-C(O)-3-14 membered heterocyclyl, —C0-6 alkylene-C(O)-5-12 membered heteroaryl, —O—C0-6 alkylene-O—C1-6 alkyl, —O—C0-6 alkylene-3-14 membered carbocyclyl, —O—C0-6 alkylene-3-14 membered heterocyclyl, —O—C0-6 alkylene-5-12 membered heteroaryl, —O—C0-6 alkylene-C5-12 aryl, and —S(O)—C1-6 alkyl;
R and R′ are each independently hydrogen, C1-6 alkyl or deuterated C1-6 alkyl, or R and R′ optionally form the 3-14 membered heterocyclyl or 5-12 membered heteroaryl together with nitrogen atoms connected to R and R′, wherein the heterocyclyl and the heteroaryl each independently contain 0, 1 or 2 heteroatoms selected from N, O and S in addition to the existing nitrogen atoms;
in the above groups, 2 hydrogen atoms on any one carbon atom on the C0-6 alkylene may further be optionally substituted by 3-7 membered carbocycle or 3-7 membered heterocyclic spirocycle at the same time; and
in the above groups, 2 hydrogen atoms on any one carbon atom on the C1-6 alkylene may further be optionally substituted by 3-7 membered carbocycle or 3-7 membered heterocyclic spirocycle at the same time.

### Claim 11 (depends on 1)

A method for inhibiting CDK7, comprising administering to a subject the compound or the pharmaceutically acceptable salt according to claim 1.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the CDK7-related disease is selected from proliferative diseases, infectious diseases, immune diseases, autoimmune diseases, and inflammatory diseases.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the proliferative disease is a tumor or cancer.
